Lyell Immunopharma's total assets for Q1 2026 were $350.63M, an increase of 3.11% from the previous quarter. LYEL total liabilities were $76.96M for the fiscal quarter, a -16.21% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.